Stryker receives FDA clearance for Incompass Total Ankle System
Get Alerts SYK Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
Revenue Growth %: +9.3%
Join SI Premium – FREE
Streamlining total ankle replacement with data-driven implants and surgical flexibility
PORTAGE, Mich.--(BUSINESS WIRE)-- Stryker (NYSE: SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/

Stryker's Incompass® Total Ankle System integrates the technologies of the Inbone® and Infinity® systems into a single, comprehensive solution.
“Incompass reflects our commitment to redefining what’s possible in total ankle replacement,” said Adam Jacobs, vice president and general manager of Stryker’s Foot & Ankle business. “By building on decades of clinical experience and leveraging extensive data insights, we’re setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.”
Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care.
Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company’s Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Copyright © 2025 Stryker
Content ID: FA-INCO-PRESS-2016296
References:
1. Based on internal data as of 5/1/2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625296275/en/
Media contact
Sampson Public Relations Group
Andrea Sampson
President/CEO [email protected]
Source: Stryker
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- $9.5 Billion Focus Financial Network Expands to East Coast with Advisor Jennifer McDonald
- Green Mobility in Africa — UNDP and TAILG Sign MOU for a Green, Low-Carbon Mobility Project to Advance Sustainable Development in Africa and Beyond
- MixTwix.io Introduces a Privacy-Focused Digital Asset Information Platform for Users Seeking Better Transaction Awareness and Security
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share